Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
ENTRY CRITERIA:~DISEASE CHARACTERISTICS:~* Locally advanced or metastatic malignancies~* Histologically or cytologically confirmed~* Evaluable~* Surgically and medically incurable~* Not responding to standard therapy or no other standard therapy exists~* Human leukocyte antigen (HLA)-A2.1/p53 positive~PRIOR/CONCURRENT THERAPY:~* No prior Proleukin therapy within one year~* No concurrent radiotherapy, chemotherapy, or other immunotherapy~* More than 4 weeks since prior major radiotherapy~* More than 4 weeks since prior cytotoxic therapy~* More than 6 weeks since prior nitrosoureas therapy~* More than 8 weeks since prior monoclonal antibody therapy~PATIENT CHARACTERISTICS:~Life expectancy~* \> 3 months~Performance status~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1~Bone marrow reserve~* Absolute neutrophil count (AGC/ANC) ≥ 1,500/microliters (uL)~* Platelets ≥100,000/uL~* Hemoglobin ≥ 10g/dL~Renal function~* Serum creatinine ≤ 1.5 X Upper limit of normal (ULN)~Hepatic function~* Total bilirubin ≤ 1.5 X ULN~* Aspartate Aminotransferase (AST) ≤ 2.5 X ULN~* Alkaline phosphatase ≤ 2.5 X ULN~* Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 X ULN~* Activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN~Cardiovascular~* May be safely tapered off anti-hypertensives if currently on anti-hypertensives~* New York Heart Association classification I or II~* No congestive heart failure \<6 months~* No unstable angina pectoris \<6 months~* No myocardial infarction \<6 months~* No history of ventricular arrhythmias~* Normal cardiac stress test required if any of the following is present:~  * Over age 50~ * History of abnormal EKG~ * Symptoms of cardiac ischemia or arrhythmia~Pulmonary~* Normal pulmonary function test (FEV1 ≥ 75% of predicted value) if any of the following is present:~  * Prolonged history of cigarette smoking~ * Symptoms of respiratory dysfunction~Other~* No known autoimmune disease~* No known HIV positive~* No psychiatric illness/social situations that would limit study compliance~* No history or evidence of central nervous system (CNS) disease~* No active systemic infection requiring parental antibiotic therapy~* No systemic steroid therapy required~* No prior organ allograft~* Not receiving other investigational agents~* Not receiving chronic medication for asthma~* Not pregnant or nursing~* Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).